In this context, analyses of larger cohorts of patients taking into consideration other factors affecting EC prognosis such as the presence of POLE and p53 mutation, mismatch repair (MMR) status, the levels of L1CAM and estrogen/progesterone receptors’ positivity in the tumor, etc., need to be done for more specific assessment of the significance of circulating marker serum levels. This evidence concerns the gene POLE and neoplasm.